Form PTO-1449 (Modified)
(Rev. 11/92)

U.S. Dept. of Commerce
Patent and Trademark Office

OIPE
JUL 0 2 2001
PATENT & TRADEMARK OFFICE

RECEIVED
JUL 0 9 2001
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

ATTY. DOCKET NO.	SERIAL NO.
LUD-5543.3 US	09/[illegible],797
APPLICANT	
Laura Dumoutier, et al.	
FILING DATE	GROUP
December 29, 2000	UNKNOWN

U.S. PATENT DOCUMENTS

*Examiner Initial	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	99/61617	12/2/99	WO	—	—	—	—
	00/65027	11/2/00	WO	—	—	—	—

OTHER DOCUMENTS
(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

NO		Parrish-Novak, et al., "Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function," Nature 408:57-63 (November 2, 2000)
NO		Xie, et al., "Interleukin (IL-22), a Novel Human Cytokine That Signals Through the Interleukin Receptor-related proteins CRF 2-4 and IL-22R." J. Biol. Chem 275 (40):51335-51339 (October 6, 2000)

EXAMINER	DATE CONSIDERED
[signature]	6-24-02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.